Clinical Trial

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The study terminated because the clinical development programme for Ceralasertib has been discontinued.
Summary
The study aims to assess the effect of ceralasertib on the pharmacokinetics (PK) of Drug X, Drug Y and Drug Z in participants with advanced solid tumours.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-04-14; most recent amendment 2026-07-23.
Status change: Recruiting → Terminated 2026-01-21
Status change: Not Yet Recruiting → Recruiting 2025-05-29
Trial Details
NCT Number NCT06929260
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Advanced Solid Tumours
Enrollment 1 participants
Start Date 2025-05-21
Primary Completion 2025-10-15 (estimated)
Study Completion 2025-12-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-24